entecavir / Generic mfg. - LARVOL DELTA

Stopping Antiviral Treatment in Chronic Hepatitis B (clinicaltrials.gov) - P=N/A | N=54 | Active, not recruiting | Sponsor: The University of Hong Kong | Trial primary completion date: Dec 2023 ➔ Aug 2025 | Trial completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Hepatitis B • Infectious Disease • Inflammation

A Severe, Refractory Case of Adult-Onset Anti-NMDAR Encephalitis (ACTRIMS Forum 2026) - "Her seizures were resolved and after completing a week of Entecavir for hepatitis B prophylaxis, she was given Rituximab on day 23 and day 30. Third-line treatments such as Tocilizumab were considered, however, it was deemed unsafe to initiate immediately after Rituximab due to her immunosuppressed state and recurrent gastrointestinal bleeding and infection during her hospitalization... Risks of nosocomial infections pose a significant challenge for treatment of refractory NMDAR encephalitis. Further studies are needed to guide clinical approach for this disease that requires nuanced management."

Clinical • CNS Disorders • Dyslipidemia • Dystonia • Epilepsy • Gastroenterology • Hepatitis B • Hepatology • Immunology • Infectious Disease • Migraine • Movement Disorders • Septic Shock

Genotype-specific Response to 144-week Entecavir Therapy for HBeAg-positive Chronic Hepatitis B with a Particular Focus on Histological Improvement: A Prospective Study. (PubMed, J Clin Transl Hepatol) - "HBV genotype B demonstrates superior histological responses to ETV therapy compared with genotype C, supporting the clinical value of HBV genotyping for personalized CHB management. These findings highlight the importance of considering viral genotype when evaluating treatment outcomes."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation

EFFECTIVENESS OF A STRUCTURED PREVENTION STRATEGY FOR HBV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING HBSAG-POSITIVE DONORS (EBMT 2026) - P=N/A | "Donors with detectable HBV DNA received entecavir 0.5 mg/day until completion of stem cell collection... This prospective study demonstrates that a novel HBV management strategy is feasible and associated with excellent hepatic safety, with no liver-related mortality observed. Although HBVr occurred, it was clinically manageable. Substantial heterogeneity in HBVr risk was observed among HBsAg-negative recipients with different baseline serologic profiles, providing important insights for the future refinement of risk-stratified preventive strategies."

Bone Marrow Transplantation • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Transplantation

Comparative effectiveness of tenofovir versus entecavir combined with peginterferon Alfa-2b for functional cure in HBeAg-negative chronic hepatitis B: a propensity score-matched analysis. (PubMed, BMC Infect Dis) - No abstract available

HEOR • Journal • Hepatitis B • Infectious Disease • Inflammation

A case report of agranulocytosis caused by acute hepatitis B virus infection. (PubMed, Medicine (Baltimore)) - "This case highlights acute HBV infection as a causative factor for severe neutropenia/agranulocytosis. Importantly, the study reveals that early antiviral treatment can not only suppress viral replication but also reverse bone marrow suppression, leading to complete hematologic recovery and functional cure (hepatitis B surface antigen seroconversion). This study demonstrates that antiviral therapy is necessary for the management of acute HBV with severe hematologic complications."

Journal • Agranulocytosis • Anorexia • Fatigue • Granulocytopenia • Hematological Disorders • Hepatitis B • Infectious Disease • Inflammation • Leukopenia • Neutropenia

Intracranial hepatitis B virus (HBV) infection following intracerebral hemorrhage in a patient with seronegative occult HBV infection. (PubMed, IDCases) - "After 8 weeks of treatment with entecavir, the HBV loads in the serum and CSF decreased significantly, the patient's consciousness improved, and the patient's temperature returned to normal. This study first reported a seronegative OBI patient developing intracranial HBV infection following intracerebral hemorrhage and clarified the diagnostic value of mNGS in rare intracranial infections."

Journal • Cerebral Hemorrhage • Hematological Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection-General and Special Populations. (PubMed, Aliment Pharmacol Ther) - "Current first-line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD."

Journal • Review • Chronic Kidney Disease • Diabetes • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Nephrology • Renal Disease • Transplantation

Comparison of antiviral efficacy of nucleos(t)ide analogue monotherapy and its combination with interferon-α in children 1-6 years-old with HBeAg-positive chronic hepatitis B (PubMed, Zhonghua Gan Zang Bing Za Zhi) - "Oral lamivudine or entecavir and interferon-α (IFN-α) or pegylated interferon-α (PEG-IFN-α) were administered to the NA and NA+IFN groups... The antiviral efficacy of the NA+IFN combination therapy group was superior to that of the NA monotherapy group at 48 weeks in children with CHB 4-6 years old. However, there was no statistically significant difference in the efficacy of the two antiviral regimens among young children 1-3 years old, hinting that NA therapy may be a priority for young children."

Clinical • Journal • Monotherapy • Hepatitis B • Infectious Disease • Inflammation • IFNA1

ALEH position statement on the management of hepatitis B virus infection 2025. (PubMed, Ann Hepatol) - "Expanded treatment criteria include patients with significant fibrosis, elevated HBV DNA levels, co-infections, and other risk factors, ensuring broader access to antiviral therapy with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV). Additionally, universal HDV testing in HBV-infected patients is recommended. These guidelines highlight the urgent need for decentralization, simplification, and equity in HBV management to achieve elimination goals in Latin America by 2030."

Clinical guideline • Journal • Fibrosis • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Oncology • Solid Tumor

Multidisciplinary management of thyroid eye disease (TED) in patients with latent tuberculosis or chronic hepatitis B. (PubMed, Thyroid Res) - "Immunosuppression can be safely initiated in TED patients with systemic infections using a multidisciplinary approach. Early screening, judicious patient selection, coordinated care, and prophylactic treatment are key to balancing efficacy with risk mitigation."

Journal • Hepatitis B • Infectious Disease • Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Thyroid Eye Disease • Tuberculosis

Letter: Concerns Regarding the Paradoxical Renal Outcomes in Patients Switching From Entecavir to Tenofovir Alafenamide in the Study by Ogawa et al. (PubMed, J Gastroenterol Hepatol) - No abstract available

Journal

Reply to "Concerns Regarding the Paradoxical Renal Outcomes in Patients Switching From Entecavir to Tenofovir Alafenamide". (PubMed, J Gastroenterol Hepatol) - No abstract available

Journal

Detectability of hepatitis B virus DNA in peripheral blood mononuclear cells following long-term nucleos(t)ide analogue therapy-induced sustained viral suppression. (PubMed, Eur J Gastroenterol Hepatol) - "HBV DNA may persist in PBMCs despite long-term nucleos(t)ide analogue therapy-induced sustained viral suppression. Pretreatment HBeAg positivity and elevated posttreatment qHBsAg can help identify patients at risk, highlighting the need to monitor extrahepatic reservoirs in CHB management."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation

Letter to the editor: "Critical appraisal of the anchor RCT on entecavir, peginterferon Alfa-2b, and GM-CSF combination therapy". (PubMed, Hepatol Int) - No abstract available

Journal • CSF2

Case Report: A rare pediatric case of hepatitis B virus infection with acute disseminated encephalomyelitis/Guillain-Barré syndrome spectrum diseases. (PubMed, Front Pediatr) - "In this case, the combination of hormones and intravenous immunoglobulin did not affect the anti-HBV effect of entecavir, and the patient fully recovered from the neurological damage within three months of disease onset. This case highlights hepatitis B-related neurological diseases and encourages further sharing of clinical experiences."

Journal • CNS Disorders • Epilepsy • Hepatitis B • Infectious Disease • Inflammation • Multiple Sclerosis • Pediatrics

Entecavir provides favorable virological control but minimal metabolic benefit in patients with Chronic Hepatitis B and MAFLD. (PubMed, Am J Transl Res) - "Entecavir can effectively control viral replication in patients with CHB combined with MAFLD. However, the recovery of liver function, improvement of steatosis and improvement of metabolic indicators were all slightly inferior to those of the non-MAFLD population, suggesting that the coexistence of MAFLD may weaken the comprehensive benefits of antiviral treatment."

Journal • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Dysfunction-Associated Steatotic Liver Disease

Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: Qing-Lei Zeng

New P4 trial • Hepatitis B • Infectious Disease • Inflammation

Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B (clinicaltrials.gov) - P4 | N=80 | Not yet recruiting | Sponsor: Qing-Lei Zeng

New P4 trial • Hepatitis B • Infectious Disease • Inflammation

qHBsAg outperforms ALT/qHBsAg ratio in predicting HBsAg seroclearance after cessation of entecavir versus tenofovir. (PubMed, Biomed J) - "A qHBsAg level <100 IU/mL at EOT is better predictor of HBsAg seroclearance than an ALT/qHBsAg ratio ≥0.2. Compared to TDF, entecavir was associated with higher rates of HBsAg seroclearance in patients with higher qHBsAg level or a lower ALT/qHBsAg ratio at EOT."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation

A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) (clinicaltrials.gov) - P1 | N=47 | Terminated | Sponsor: Arrowhead Pharmaceuticals | Phase classification: P1a/1b ➔ P1

Phase classification • Hepatitis B • Infectious Disease • Inflammation

Inhibitor screening identifies Entecavir as a promising candidate targeting human eIF4E to block cap-dependent translation in cancer: an integrated in silico and in vitro study. (PubMed, J Comput Aided Mol Des) - "Our findings not only reinforce the feasibility of targeting eIF4E in cancer but also demonstrate that repurposing FDA-approved drugs like Entecavir could offer a practical and efficient route to therapeutic intervention. This integrative approach opens new avenues for eIF4E-targeted strategies in oncology, aiming to selectively impair oncogenic translation."

Journal • Preclinical • Hepatitis B • Infectious Disease • Oncology • EIF4E

Eligibility for hepatitis B virus (HBV) treatment and prevalence of drug resistance in a Ugandan population cohort. (PubMed, J Infect) - "While the WHO 2024 treatment criteria offer an opportunity to expand access to care, there is a need to determine how assessment tools differ in determination of eligibility in different settings. HBVDR remains uncommon but more research is needed to understand its prevalence and clinical impact in African populations."

Journal • Fibrosis • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Repurposing of FDA-Approved Antiviral Drugs Against Monkeypox Virus: Comparative In Vitro Screening and Structure Based In Silico Studies. (PubMed, Pharmaceuticals (Basel)) - "Twenty-three FDA-approved drugs, including Abacavir, Acyclovir, Amantadine, Chloroquine, Daclatasvir, Dolutegravir, Entecavir, Favipiravir, Hydroxychloroquine, Lamivudine, Molnupiravir, Nevirapine, Oseltamivir, Penciclovir, Remdesivir, Ribavirin, Sofosbuvir, Tenofovir, Valaciclovir, Valganciclovir, Velpatasvir, Zanamivir, and Zidovudine, were screened for potential anti-monkeypox activity in vitro...The employed computational methods indicate that remdesivir demonstrated superior binding patterns with elevated scores and stable complexes throughout the simulation. Our findings showed that Remdesivir therapeutic compound is potent against the tested strain of MPXV, and exhibited a robust binding affinity for Thymidylate Kinase, A42R Profilin-Like Protein, and VACV D13 enzymes, and thus may potentially be utilized as antiviral for the treatment of monkeypox virus."

FDA event • Journal • Preclinical • Infectious Disease

Nucleos(t)ide analogue treatment in hepatitis B: to stop or not to stop? (PubMed, Expert Rev Anti Infect Ther) - "Monotherapy with a nucleos(t)ide analogue (NA), namely entecavir and tenofovir, represents the mainstay of hepatitis B virus (HBV) treatment, which achieves potent viral suppression and subsequently improved major outcomes, but it rarely leads to functional cure (ie...In the absence of novel antivirals leading to HBsAg clearance, accumulating data suggests that stopping NA therapy in carefully selected HBeAg negative patients may increase the probability of HBsAg loss and reduce long-term treatment burden eventually improving patients' outcome. However, there are risks of post-treatment relapses and flares that need to be considered, while other critical parameters should be fitted to tailor patient selection."

Journal • Review • Hepatitis B • Infectious Disease • Inflammation • Liver Cirrhosis